US Pharm. 2011;36(4):42. 

Glenmark Generics Inc., the U.S. subsidiary of Glenmark Generics Limited, announced that it has been granted final approval for its ANDA from the FDA for levocetirizine dihydrochloride 5-mg tablets, the generic version of UCB Inc.'s Xyzal tablets.
Glenmark's levocetirizine dihydrochloride tablets are currently available. Total U.S. sales as reported by IMS Health for the 12-month period ending December 2010 were approximately $231 million.